83 related articles for article (PubMed ID: 19372577)
1. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
de Vries TJ; Mullender MG; van Duin MA; Semeins CM; James N; Green TP; Everts V; Klein-Nulend J
Mol Cancer Res; 2009 Apr; 7(4):476-88. PubMed ID: 19372577
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
Schweppe RE; Kerege AA; French JD; Sharma V; Grzywa RL; Haugen BR
J Clin Endocrinol Metab; 2009 Jun; 94(6):2199-203. PubMed ID: 19293266
[TBL] [Abstract][Full Text] [Related]
3. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo.
Whyte LS; Ryberg E; Sims NA; Ridge SA; Mackie K; Greasley PJ; Ross RA; Rogers MJ
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16511-6. PubMed ID: 19805329
[TBL] [Abstract][Full Text] [Related]
4. Reduced form of Galectin-1 Suppresses Osteoclastic Differentiation of Human Peripheral Blood Mononuclear Cells and Murine RAW264 Cells In Vitro.
Takeuchi T; Oyama M; Tamura M; Arata Y; Hatanaka T
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254721
[TBL] [Abstract][Full Text] [Related]
5. Redox signaling and antioxidant defense in osteoclasts.
Tao H; Li X; Wang Q; Yu L; Yang P; Chen W; Yang X; Zhou J; Geng D
Free Radic Biol Med; 2024 Feb; 212():403-414. PubMed ID: 38171408
[TBL] [Abstract][Full Text] [Related]
6. Manzamine-A Alters
Maykovich T; Hardy S; Hamann MT; Cray J
J Nat Prod; 2024 Mar; 87(3):560-566. PubMed ID: 38383319
[TBL] [Abstract][Full Text] [Related]
7. Targeting initial tumour-osteoclast spatiotemporal interaction to prevent bone metastasis.
Gu C; Chen P; Tian H; Yang Y; Huang Z; Yan H; Tang C; Xiang J; Shangguan L; Pan K; Chen P; Huang Y; Liu Z; Tang R; Fan S; Lin X
Nat Nanotechnol; 2024 Mar; ():. PubMed ID: 38499860
[TBL] [Abstract][Full Text] [Related]
8. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Heusschen R; Muller J; Binsfeld M; Marty C; Plougonven E; Dubois S; Mahli N; Moermans K; Carmeliet G; Léonard A; Baron F; Beguin Y; Menu E; Cohen-Solal M; Caers J
Oncotarget; 2016 May; 7(21):30712-29. PubMed ID: 27095574
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.
Gucalp A; Sparano JA; Caravelli J; Santamauro J; Patil S; Abbruzzi A; Pellegrino C; Bromberg J; Dang C; Theodoulou M; Massague J; Norton L; Hudis C; Traina TA
Clin Breast Cancer; 2011 Oct; 11(5):306-11. PubMed ID: 21729667
[TBL] [Abstract][Full Text] [Related]
11. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule amines: a big role in the regulation of bone homeostasis.
Zhang Q; Yang J; Hu N; Liu J; Yu H; Pan H; Chen D; Ruan C
Bone Res; 2023 Jul; 11(1):40. PubMed ID: 37482549
[TBL] [Abstract][Full Text] [Related]
13. Zika virus infects human osteoclasts and blocks differentiation and bone resorption.
Mumtaz N; Koedam M; van Leeuwen JPTM; Koopmans MPG; van der Eerden BCJ; Rockx B
Emerg Microbes Infect; 2022 Dec; 11(1):1621-1634. PubMed ID: 35670284
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy.
Sharma S; Carlson S; Gregory-Flores A; Hinojo-Perez A; Olson A; Thippeswamy T
Neurobiol Dis; 2021 Aug; 156():105410. PubMed ID: 34087381
[TBL] [Abstract][Full Text] [Related]
15. A Synthetic Peptide, CK2.3, Inhibits RANKL-Induced Osteoclastogenesis through BMPRIa and ERK Signaling Pathway.
Nguyen J; Kelly S; Wood R; Heubel B; Nohe A
J Dev Biol; 2020 Jul; 8(3):. PubMed ID: 32660129
[TBL] [Abstract][Full Text] [Related]
16. Osteoclast Signal Transduction During Bone Metastasis Formation.
Győri DS; Mócsai A
Front Cell Dev Biol; 2020; 8():507. PubMed ID: 32637413
[TBL] [Abstract][Full Text] [Related]
17. Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.
Baird K; Glod J; Steinberg SM; Reinke D; Pressey JG; Mascarenhas L; Federman N; Marina N; Chawla S; Lagmay JP; Goldberg J; Milhem M; Loeb DM; Butrynski JE; Turpin B; Staddon A; Spunt SL; Jones RL; Rodler ET; Schuetze SM; Okuno SH; Helman L
Sarcoma; 2020; 2020():7935475. PubMed ID: 32398945
[TBL] [Abstract][Full Text] [Related]
18. An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain.
Danson S; Mulvey MR; Turner L; Horsman J; Escott K; Coleman RE; Ahmedzai SH; Bennett MI; Andrew D
J Bone Oncol; 2019 Dec; 19():100261. PubMed ID: 31667062
[TBL] [Abstract][Full Text] [Related]
19. Non-Viral Delivery System and Targeted Bone Disease Therapy.
Qadir A; Gao Y; Suryaji P; Tian Y; Lin X; Dang K; Jiang S; Li Y; Miao Z; Qian A
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699924
[TBL] [Abstract][Full Text] [Related]
20. Raddeanin A suppresses breast cancer-associated osteolysis through inhibiting osteoclasts and breast cancer cells.
Wang Q; Mo J; Zhao C; Huang K; Feng M; He W; Wang J; Chen S; Xie Z; Ma J; Fan S
Cell Death Dis; 2018 Mar; 9(3):376. PubMed ID: 29515110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
